STOCK TITAN

QHSLab uses $335K cash, issues going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

QHSLab, Inc. (USAQ) reported nine-month revenue of $2,253,347, up 13.4% from $1,987,931, with Integrated Service Program revenue rising 63.9% to $1,287,692. Third-quarter revenue fell 8.1% to $677,172 from $737,066 as existing physician customers bought fewer allergy-related products; ISP revenue partly offset the decline. Nine-month gross margin was 67.9%, compared with 66.5%.

Operating expenses contributed to a $99,539 operating loss, versus $95,738 operating income a year earlier; net loss was $119,021 versus $99,156. Operating activities used $334,989 of cash, compared with $80,085 generated in the 2025 nine-month period, and cash stood at $190,464 on September 30, 2026. The company reported a $4,022,572 accumulated deficit and said its losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern. Management concluded disclosure controls were ineffective, citing inadequate financial-reporting personnel, and identified corrective actions. It also moved to order-based fulfillment and had no inventory on hand at quarter-end.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 5 points

How the balance works

Positive

  • Moderate pointNine-month revenue rose 13.4% to $2,253,347.
  • Minor pointIntegrated Service Program revenue rose 63.9% to $1,287,692.

Negative

  • Major pointQHSLab disclosed substantial doubt about its ability to continue as a going concern.
  • Moderate pointThird-quarter revenue declined 8.1% to $677,172.
  • Moderate pointNine-month net loss was $119,021, versus $99,156.
  • Moderate pointOperating activities used $334,989 of cash, versus $80,085 generated a year earlier.
  • Moderate pointDisclosure controls were ineffective as of September 30, 2026.

Filing Explained

The 8,461,550 excluded common-equivalent shares were not issued common stock; conversion or exercise could enlarge the share count.

At September 30, 2026, QHSLab had 15,032,788 common shares outstanding, the same count shown at January 1, 2026. Preferred shares were convertible and 416,666 warrants were exercisable, while the nine-month equity statement shows no new common-share issuance. If converted or exercised into newly issued common shares, they would increase the share count and reduce existing holders’ ownership percentages, absent offsetting changes.

The filing lists 8,461,550 common-equivalent shares excluded from diluted loss per share: 8,044,884 linked to preferred stock and 416,666 warrants.

Series A and Series A-2 preferred stock vote with common stock and rank ahead of it in liquidation; Series A-2 also carries cumulative 7% annual dividends, payable in cash or common shares at the company’s election.

The company reported $97,816 due to related parties as a current liability, including a $90,000 loan and accrued interest; some advances are due on demand, and the loan matures March 31, 2027.

Nine-month revenue $2,253,347, up 13.4% from $1,987,931 Nine months ended September 30, 2026, compared with 2025
Third-quarter revenue $677,172, down 8.1% from $737,066 Three months ended September 30, 2026, compared with 2025
Integrated Service Program revenue $1,287,692, up 63.9% from $785,506 Nine months ended September 30, 2026, compared with 2025
Net loss $119,021, compared with $99,156 Nine months ended September 30, 2026, compared with 2025
Cash from operating activities $334,989 used, compared with $80,085 provided Nine months ended September 30, 2026, compared with 2025
Gross margin 67.9%, compared with 66.5% Nine months ended September 30, 2026, compared with 2025
Cash and cash equivalents $190,464 As of September 30, 2026
Accumulated deficit $4,022,572 As of September 30, 2026
substantial doubt financial
"raise substantial doubt about the Company’s ability to continue as a going concern"
Integrated Service Program financial
"a 63.9% increase in revenues generated from ISP services"
order-based fulfillment model technical
"transitioned to an order-based fulfillment model"
gross margin financial
"Gross margin increased from 66.5% to 67.9%"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
valuation allowance financial
"continues to maintain a valuation allowance against its net deferred tax assets"
A valuation allowance is a reserve set aside to reduce the value of certain assets on a company's financial records when there is uncertainty about whether they will generate the expected benefits. It acts like a caution sign, indicating that some assets might not be fully recoverable or worth their recorded amount. This matters to investors because it provides a more realistic picture of a company's financial health and potential risks.
anti-dilutive financial
"inclusion would be anti-dilutive for the period"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did USAQ report for the first nine months of 2026?

QHSLab reported revenue of $2,253,347 for the nine months ended September 30, 2026, compared with $1,987,931 in the same period of 2025. Integrated Service Program revenue was $1,287,692, compared with $785,506. The company attributed the overall increase primarily to growth in ISP services.

What cost reduction does USAQ expect from its vendor changes?

QHSLab said vendor relationship changes implemented in September 2026 are expected to reduce allergy diagnostic kit costs by approximately 10% to 13%, based on historical product sales mix and revised supplier pricing. Management said the effect on future gross margins will depend on sales volumes and product mix.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0000856984 0000856984 2026-01-01 2026-09-30 0000856984 2026-11-12 0000856984 2026-09-30 0000856984 2025-12-31 0000856984 us-gaap:SeriesAPreferredStockMember 2026-09-30 0000856984 us-gaap:SeriesAPreferredStockMember 2025-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember 2026-09-30 0000856984 USAQ:SeriesATwoPreferredStockMember 2025-12-31 0000856984 2026-07-01 2026-09-30 0000856984 2025-07-01 2025-09-30 0000856984 2025-01-01 2025-09-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-12-31 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2025-12-31 0000856984 us-gaap:CommonStockMember 2025-12-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000856984 us-gaap:RetainedEarningsMember 2025-12-31 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2026-03-31 0000856984 us-gaap:CommonStockMember 2026-03-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000856984 us-gaap:RetainedEarningsMember 2026-03-31 0000856984 2026-03-31 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-06-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2026-06-30 0000856984 us-gaap:CommonStockMember 2026-06-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000856984 us-gaap:RetainedEarningsMember 2026-06-30 0000856984 2026-06-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2024-12-31 0000856984 us-gaap:CommonStockMember 2024-12-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000856984 us-gaap:RetainedEarningsMember 2024-12-31 0000856984 2024-12-31 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-03-31 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2025-03-31 0000856984 us-gaap:CommonStockMember 2025-03-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000856984 us-gaap:RetainedEarningsMember 2025-03-31 0000856984 2025-03-31 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-06-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2025-06-30 0000856984 us-gaap:CommonStockMember 2025-06-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000856984 us-gaap:RetainedEarningsMember 2025-06-30 0000856984 2025-06-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-03-31 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2026-01-01 2026-03-31 0000856984 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000856984 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000856984 2026-01-01 2026-03-31 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-04-01 2026-06-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2026-04-01 2026-06-30 0000856984 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000856984 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000856984 2026-04-01 2026-06-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-07-01 2026-09-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2026-07-01 2026-09-30 0000856984 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000856984 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-03-31 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2025-01-01 2025-03-31 0000856984 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000856984 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000856984 2025-01-01 2025-03-31 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-04-01 2025-06-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2025-04-01 2025-06-30 0000856984 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000856984 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000856984 2025-04-01 2025-06-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2025-07-01 2025-09-30 0000856984 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000856984 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2026-09-30 0000856984 us-gaap:CommonStockMember 2026-09-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0000856984 us-gaap:RetainedEarningsMember 2026-09-30 0000856984 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-09-30 0000856984 us-gaap:PreferredStockMember USAQ:SeriesATwoPreferredStockMember 2025-09-30 0000856984 us-gaap:CommonStockMember 2025-09-30 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000856984 us-gaap:RetainedEarningsMember 2025-09-30 0000856984 2025-09-30 0000856984 2025-01-01 2025-12-31 0000856984 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerOneMember 2026-07-01 2026-09-30 0000856984 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerTwoMember 2026-07-01 2026-09-30 0000856984 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerOneMember 2026-01-01 2026-09-30 0000856984 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerOneMember 2025-07-01 2025-09-30 0000856984 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerOneMember 2025-01-01 2025-09-30 0000856984 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerOneMember 2026-01-01 2026-09-30 0000856984 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerTwoMember 2026-01-01 2026-09-30 0000856984 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerThreeMember 2026-01-01 2026-09-30 0000856984 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerOneMember 2025-01-01 2025-12-31 0000856984 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember USAQ:CustomerTwoMember 2025-01-01 2025-12-31 0000856984 us-gaap:PatentsMember 2026-09-30 0000856984 USAQ:WebDomainMember 2026-01-01 2026-09-30 0000856984 USAQ:TrademarkMember 2026-01-01 2026-09-30 0000856984 USAQ:IntegratedServiceProgramMember 2026-07-01 2026-09-30 0000856984 USAQ:IntegratedServiceProgramMember 2025-07-01 2025-09-30 0000856984 USAQ:IntegratedServiceProgramMember 2026-01-01 2026-09-30 0000856984 USAQ:IntegratedServiceProgramMember 2025-01-01 2025-09-30 0000856984 USAQ:AllergyDiagnosticKitSalesMember 2026-07-01 2026-09-30 0000856984 USAQ:AllergyDiagnosticKitSalesMember 2025-07-01 2025-09-30 0000856984 USAQ:AllergyDiagnosticKitSalesMember 2026-01-01 2026-09-30 0000856984 USAQ:AllergyDiagnosticKitSalesMember 2025-01-01 2025-09-30 0000856984 USAQ:ImmunotherapyTreatmentSalesMember 2026-07-01 2026-09-30 0000856984 USAQ:ImmunotherapyTreatmentSalesMember 2025-07-01 2025-09-30 0000856984 USAQ:ImmunotherapyTreatmentSalesMember 2026-01-01 2026-09-30 0000856984 USAQ:ImmunotherapyTreatmentSalesMember 2025-01-01 2025-09-30 0000856984 USAQ:ClinicalStudyRevenueMember 2026-07-01 2026-09-30 0000856984 USAQ:ClinicalStudyRevenueMember 2025-07-01 2025-09-30 0000856984 USAQ:ClinicalStudyRevenueMember 2026-01-01 2026-09-30 0000856984 USAQ:ClinicalStudyRevenueMember 2025-01-01 2025-09-30 0000856984 USAQ:SubscriptionRevenueMember 2026-07-01 2026-09-30 0000856984 USAQ:SubscriptionRevenueMember 2025-07-01 2025-09-30 0000856984 USAQ:SubscriptionRevenueMember 2026-01-01 2026-09-30 0000856984 USAQ:SubscriptionRevenueMember 2025-01-01 2025-09-30 0000856984 us-gaap:ShippingAndHandlingMember 2026-07-01 2026-09-30 0000856984 us-gaap:ShippingAndHandlingMember 2025-07-01 2025-09-30 0000856984 us-gaap:ShippingAndHandlingMember 2026-01-01 2026-09-30 0000856984 us-gaap:ShippingAndHandlingMember 2025-01-01 2025-09-30 0000856984 USAQ:TrainingAndOtherRevenueMember 2026-07-01 2026-09-30 0000856984 USAQ:TrainingAndOtherRevenueMember 2025-07-01 2025-09-30 0000856984 USAQ:TrainingAndOtherRevenueMember 2026-01-01 2026-09-30 0000856984 USAQ:TrainingAndOtherRevenueMember 2025-01-01 2025-09-30 0000856984 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2026-09-30 0000856984 us-gaap:PatentsMember 2025-12-31 0000856984 USAQ:WebDomainMember 2026-09-30 0000856984 USAQ:WebDomainMember 2025-12-31 0000856984 us-gaap:TrademarksMember 2026-09-30 0000856984 us-gaap:TrademarksMember 2025-12-31 0000856984 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2026-07-01 2026-09-30 0000856984 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-07-01 2025-09-30 0000856984 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2026-01-01 2026-09-30 0000856984 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-01-01 2025-09-30 0000856984 us-gaap:TrademarksMember 2021-06-23 2021-06-23 0000856984 us-gaap:TrademarksMember 2026-07-01 2026-09-30 0000856984 us-gaap:TrademarksMember 2025-07-01 2025-09-30 0000856984 us-gaap:TrademarksMember 2026-01-01 2026-09-30 0000856984 us-gaap:TrademarksMember 2025-01-01 2025-09-30 0000856984 2025-11-12 2025-11-12 0000856984 USAQ:NoteOneShareholderMember 2026-09-30 0000856984 USAQ:NoteOneShareholderMember 2025-12-31 0000856984 USAQ:ConvertibleNotesPayableOneMember 2021-05-07 0000856984 USAQ:ConvertibleNotesPayableOneMember USAQ:NoteOneShareholderMember 2021-05-07 0000856984 USAQ:ConvertibleNotesPayableOneMember USAQ:NoteOneShareholderMember 2021-05-07 2021-05-07 0000856984 USAQ:ConvertibleNotesPayableOneMember USAQ:NoteOneShareholderMember 2026-09-30 0000856984 USAQ:ConvertibleNotesPayableOneMember USAQ:NoteOneShareholderMember 2025-12-31 0000856984 USAQ:SubscriptionAgreementsMember us-gaap:PrivatePlacementMember 2025-12-26 2025-12-26 0000856984 USAQ:SubscriptionAgreementsMember us-gaap:PrivatePlacementMember 2025-12-26 0000856984 us-gaap:SeriesAPreferredStockMember 2021-06-21 0000856984 USAQ:SeriesA2PreferredStockMember 2021-12-29 2021-12-30 0000856984 USAQ:SeriesA2PreferredStockMember 2026-01-01 2026-09-30 0000856984 USAQ:SeriesA2PreferredStockMember 2025-01-01 2025-12-31 0000856984 USAQ:CommonEquivalentSharesMember 2026-07-01 2026-09-30 0000856984 USAQ:CommonEquivalentSharesMember 2025-07-01 2025-09-30 0000856984 USAQ:CommonEquivalentSharesMember 2026-01-01 2026-09-30 0000856984 USAQ:CommonEquivalentSharesMember 2025-01-01 2025-09-30 0000856984 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0000856984 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0000856984 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0000856984 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0000856984 us-gaap:WarrantMember 2026-07-01 2026-09-30 0000856984 us-gaap:WarrantMember 2025-07-01 2025-09-30 0000856984 us-gaap:WarrantMember 2026-01-01 2026-09-30 0000856984 us-gaap:WarrantMember 2025-01-01 2025-09-30 0000856984 us-gaap:StockOptionMember 2026-01-01 2026-09-30 0000856984 us-gaap:StockOptionMember 2025-01-01 2025-09-30 0000856984 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0000856984 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000856984 USAQ:ResearchAndDevelopmentExpensesMember 2025-07-01 2025-09-30 0000856984 USAQ:ResearchAndDevelopmentExpensesMember 2026-07-01 2026-09-30 0000856984 USAQ:GeneralAndAdministrativeExpensesMember 2026-07-01 2026-09-30 0000856984 USAQ:GeneralAndAdministrativeExpensesMember 2025-07-01 2025-09-30 0000856984 USAQ:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-09-30 0000856984 USAQ:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-09-30 0000856984 USAQ:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-09-30 0000856984 USAQ:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-09-30 0000856984 USAQ:OptionOneMember 2025-01-01 2025-09-30 0000856984 USAQ:OptionOneMember 2025-09-30 0000856984 us-gaap:OptionMember 2025-09-30 0000856984 USAQ:WarrantOneMember 2026-01-01 2026-09-30 0000856984 USAQ:WarrantOneMember 2026-09-30 0000856984 us-gaap:WarrantMember 2026-09-30 0000856984 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0000856984 us-gaap:RelatedPartyMember 2026-09-30 0000856984 us-gaap:RelatedPartyMember 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure USAQ:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the period from ______________ to_______________

 

Commission file number 000-19041

 

QHSLab, Inc.

(Exact Name Of Registrant As Specified In Its Charter)

 

Nevada   30-1104301

(State of

Incorporation)

 

(I.R.S. Employer

Identification No.)

 

901 Northpoint Parkway, Suite 302, West Palm Beach, FL   33407
(Address of Principal Executive Offices)   (ZIP Code)

 

Registrant’s Telephone Number, Including Area Code: (929) 379-6503

 

Securities Registered Pursuant to Section 12(g) of The Act:

 

Title of Each Class   Trading Symbol(s)   Name of each Exchange on Which Registered
Common Stock, $0.0001 Par Value   USAQ   NA

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller Reporting Company ☒
  Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

On November 12, 2026, the Registrant had 15,032,788 shares of common stock outstanding.

 

 

 

 
 

 

TABLE OF CONTENTS

 

Item   Description   Page
         
    PART I - FINANCIAL INFORMATION    
         
ITEM 1.   FINANCIAL STATEMENTS.   4
ITEM 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.   19
ITEM 4.   CONTROLS AND PROCEDURES.   23
         
    PART II - OTHER INFORMATION    
         
ITEM 6.   EXHIBITS.   24

 

2
 

 

Cautionary Note Regarding Forward-Looking Statements

 

This report contains forward-looking statements. Certain of the matters discussed herein concerning, among other items, our operations, cash flows, financial position and economic performance including, in particular, future sales, product demand, competition and the effect of economic conditions, include forward-looking statements.

 

Forward-looking statements are predictive in nature and do not relate strictly to historical or current facts and generally include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Although we believe that the forward-looking statements contained in this report are based upon reasonable assumptions, these statements and other projections contained herein expressing opinions about future outcomes and non-historical information, are subject to uncertainties and, therefore, there is no assurance that the outcomes expressed in these statements will be achieved.

 

Investors are cautioned that forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the expectations expressed in forward-looking statements contained herein. Given these uncertainties, you should not place any reliance on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You are advised, however, to consult any additional disclosures we make in our reports filed with the Securities and Exchange Commission (“SEC”).

 

3
 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

Condensed Consolidated Balance Sheets – September 30, 2026 (unaudited) and December 31, 2025 5
Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2026 and 2025 (unaudited) 6
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) – Three and Nine Months Ended September 30, 2026 and 2025 (unaudited) 7
Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2026 and 2025 (unaudited) 8
Notes to the Condensed Consolidated Financial Statements (unaudited) 9

 

4
 

 

QHSLab, Inc.

Condensed Consolidated Balance Sheets

 

   September 30, 2026   December 31, 2025 
   (Unaudited)     
Assets          
Current Assets:          
Cash and cash equivalents  $190,464   $636,157 
Accounts receivable, net   308,923    190,610 
Inventory   -    35,790 
Prepaid expenses and other current assets   19,721    20,452 
Total current assets   519,108    883,009 
Non-current assets:          
Intangible assets, net   1,233,913    1,287,997 
Total assets  $1,753,021   $2,171,006 
           
Liabilities and Stockholders’ Equity (Deficit)          
Current Liabilities:          
Accounts payable  $135,616   $326,431 
Other current liabilities   13,682    17,858 
Due to related party   97,816    - 
Loans payable   -    85,571 
Convertible notes payable   -    20,000 
Total current liabilities   247,114    449,860 
Non-current Liabilities:          
Loans payable, non-current portion   -    96,218 
Total non-current liabilities   -    96,218 
Total liabilities   247,114    546,078 
           
Commitments and contingencies (Note 14)   -    - 
           
Stockholders’ Equity (Deficit):          
Preferred stock, 10,000,000 shares authorized          
Preferred stock Series A, $0.0001 par value; 1,080,092 shares issued and outstanding   108    108 
Preferred stock Series A-2, $0.0001 par value; 2,644,424 shares issued and outstanding   264    264 
           
Common stock, 900,000,000 shares authorized, $0.0001 par value; 15,032,788 shares issued and outstanding   1,503    1,503 
Additional paid-in capital   5,526,604    5,526,604 
Accumulated deficit   (4,022,572)   (3,903,551)
Total stockholders’ equity   1,505,907    1,624,928 
Total liabilities and stockholders’ equity  $1,753,021   $2,171,006 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

5
 

 

QHSLab, Inc.

Condensed Consolidated Statements of Operations

 

   Three Months   Three Months   Nine Months   Nine Months 
   Ended   Ended   Ended   Ended 
   September 30, 2026   September 30, 2025   September 30, 2026   September 30, 2025 
   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
Revenue  $677,172   $737,066   $2,253,347   $1,987,931 
                     
Cost of revenue   208,709    243,435    724,297    665,341 
                     
Gross profit   468,463    493,631    1,529,050    1,322,590 
                     
Operating expenses:                    
General and administrative   244,705    131,415    768,927    486,325 
Sales and marketing   141,060    115,168    454,974    317,277 
Research and development   115,074    132,769    350,604    369,166 
Amortization   18,028    18,028    54,084    54,084 
Total Operating expenses   518,867    397,380    1,628,589    1,226,852 
                     
Net operating income (loss)   (50,404)   96,251    (99,539)   95,738 
                     
Other income (expense):                    
Interest expense   (2,741)   (62,840)   (19,482)   (194,894)
Income (loss) before income taxes   (53,145)   33,411    (119,021)   (99,156)
Provision on income taxes   -    -    -    - 
Net income (loss)  $(53,145)  $33,411   $(119,021)  $(99,156)
                     
Basic net income (loss) per share  $(0.00)  $0.00   $(0.01)  $(0.01)
Diluted net income (loss) per share  $(0.00)  $0.00   $(0.01)  $(0.01)
Weighted average shares outstanding:                    
Basic   15,032,788    11,281,527    15,032,788    11,251,857 
Diluted   15,032,788    19,326,411    15,032,788    11,251,857 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

6
 

 

QHSLab, Inc.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

 

   Shares      Shares      Shares             
   Preferred Stock – Series A   Preferred Stock – Series A-2   Common Stock   Additional Paid-In    Accumulated   

Total

Stockholders’ Equity

 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
Balance at January 1, 2026   1,080,092   $108    2,644,424   $264    15,032,788   $1,503   $5,526,604   $(3,903,551)  $1,624,928 
Net loss   –    –    –    –    –    –    –    (103,906)   (103,906)
Balance at March 31, 2026   1,080,092   $108    2,644,424   $264    15,032,788   $1,503   $5,526,604   $(4,007,457)  $1,521,022 
Net income   –    –    –    –    –    –    –    38,030    38,030 
Balance at June 30, 2026   1,080,092   $108    2,644,424   $264    15,032,788   $1,503   $5,526,604   $(3,969,427)  $1,559,052 
Net loss   –    –    –    –    –    –    –    (53,145)   (53,145)
Balance at September 30, 2026   1,080,092   $108    2,644,424   $264    15,032,788   $1,503   $5,526,604   $(4,022,572)  $1,505,907 
                                              
Balance at January 1, 2025   1,080,092   $108    2,644,424   $264    10,806,527   $1,081   $3,722,141   $(4,331,350)  $(607,756)
Shares issued for services   –    –    –    –    100,000    10    20,990    –    21,000 
Conversion of notes payable   –    –    –    –    375,000    37    74,963    –    75,000 
Net loss   –    –    –    –    –    –    –    (79,609)   (79,609)
Balance at March 31, 2025   1,080,092   $108    2,644,424   $264    11,281,527   $1,128   $3,818,094   $(4,410,959)  $(591,365)
Net loss   –    –    –    –    –    –    –    (52,958)   (52,958)
Balance at June 30, 2025   1,080,092   $108    2,644,424   $264    11,281,527   $1,128   $3,818,094   $(4,463,917)  $(644,323)
Net income   –    –    –    –    –    –    –    33,411    33,411 
Balance at September 30, 2025   1,080,092   $108    2,644,424   $264    11,281,527   $1,128   $3,818,094   $(4,430,506)  $(610,912)

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

7
 

 

QHSLab, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   Nine Months
Ended
   Nine Months
Ended
 
   September 30, 2026   September 30, 2025 
Operating activities          
Net loss  $(119,021)  $(99,156)
Adjustments to reconcile net loss to net cash from operating activities:          
Allowance for credit losses   -    7,276 
Amortization   54,084    72,700 
Stock grant compensation   5,664    5,664 
Shares issued for services   -    21,000 
Changes in assets and liabilities:          
Accounts receivable   (118,313)   (21,318)
Inventory   35,790    15,160 
Prepaid expenses and other current assets   (4,933)   (13,331)
Accounts payable   (190,815)   (39,309)
Other current liabilities   2,555    131,399 
Cash flows from (used by) operating activities   (334,989)   80,085 
           
Financing activities:          
Proceeds from related-party borrowings   -    968 
Repayments of related-party borrowings   -    (13,536)
Repayments of loan borrowings   (110,704)   (66,294)
Cash flows used by financing activities   (110,704)   (78,862)
           
Net change in cash   (445,693)   1,223 
Cash and cash equivalents – beginning of year   636,157    157,168 
Cash and cash equivalents - end of period  $190,464   $158,391 
           
Supplemental disclosures of cash flow activity:          
Cash paid for interest  $12,751   $77,823 
Cash paid for taxes  $-   $- 
Supplemental noncash investing and financing activity:          
Debt and accrued interest converted to shares of common stock  $-   $75,000 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

8
 

 

QHSLab, Inc.

Notes to the Unaudited Condensed Consolidated Financial Statements

September 30, 2026

 

Note 1. The Company

 

QHSLab, Inc. (the “Company”) was incorporated in Delaware on September 1, 1983. In 2019, the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada. On April 19, 2022, the Company changed its name to QHSLab, Inc.

 

The Company is a healthcare technology company focused on improving preventive and value-based care through digital health solutions and point-of-care services. The Company provides healthcare organizations with technology-enabled programs designed to identify patient health risks, support clinical decision-making, improve patient engagement, and create new opportunities for practice revenue.

 

Note 2. Going Concern

 

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company had an accumulated deficit of $4,022,572 at September 30, 2026, generated a net loss of $119,021 for the nine months ended September 30, 2026 and generated net income of $457,417 for the year ended December 31, 2025, principally as a result of a gain of $1,145,695 on the extinguishment of debt. The Company used cash in operations of $334,989 in the nine months ended September 30, 2026, and generated cash from operations of $178,118 in the year ended December 31, 2025. Despite the extinguishment of much of the Company’s debt, the Company’s history of losses combined with the amount of its revenues, raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve and maintain positive cash flows and continual profitability and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Note 3. Basis of Presentation

 

The condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2025.

 

The accounting policies are described in the “Notes to the Consolidated Financial Statements” in the 2025 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

 

Segment Information

 

The Company operates as a single operating segment and single reportable segment. Operating segments are defined as components of a business that can earn revenue and incur expenses and for which discrete financial information is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM, the Chief Executive Officer (“CEO”), allocates resources and assesses performance based upon condensed consolidated financial information due to the interconnected relationship of the Company’s products to the same customers, therefore manages its business as a single operating segment. See Note 13 - Segment Information for additional information.

 

Reclassification of Prior Period Amounts

 

Certain prior-period amounts have been reclassified to conform to the current-period presentation. Specifically, certain expenses previously classified as Sales and Marketing Expenses have been reclassified to General and Administrative Expenses to better reflect the nature of the underlying costs. These reclassifications had no effect on total operating expenses, loss from operations, net loss, or stockholders’ equity as previously reported.

 

Accounting Policies

 

Use of Estimates: The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

 

9
 

 

Principles of Consolidation: The condensed consolidated financial statements include the accounts of QHSLab, Inc. and its wholly owned subsidiaries USAQ Corporation, Inc., and Medical Practice Income, Inc. All significant inter-company balances and transactions have been eliminated.

 

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. Cash and cash equivalents are maintained at banks believed to be stable, occasionally at amounts in excess of federally insured limits, which represents a concentration of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date.

 

Accounts Receivable: The Company extends unsecured credit to its customers on a regular basis. Management monitors the payments on outstanding balances and estimates future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations and adjusts the reserve for uncollectible balances as necessary based on experience. The Company controls its credit risk related to accounts receivable through credit approvals and monitoring. The Company had two customers that generated 10.3% and 16.5% of its revenue during the three months ended September 30, 2026, and one customer that generated 15.8% of its revenue during the nine months ended September 30, 2026. The Company had one customer that generated 11.6% of its revenue during the three months ended September 30, 2025, and one customer that generated 10.3% of its revenue during the nine months ended September 30, 2025. As of September 30, 2026, three customers each comprised greater than 10% of the outstanding accounts receivable balance at 11.1%, 11.3% and 22.5%. As of December 31, 2025, two customers comprised greater than 10% of the outstanding accounts receivable balance at 16.7% and 10.2%.

 

Inventories: Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine its cost basis for inventories. Inventories consist of only finished goods. Management monitors inventory based on forecasted sales and existing inventory levels. Based on inventory turnover and low on-hand inventory levels, management has determined there was no need for a reserve for slow-moving and obsolete inventories as of December 31, 2025. During the quarter ended September 30, 2026, the Company transitioned to an order-based fulfillment model under which products are purchased and fulfilled based on customer orders rather than maintained as inventory on hand. Accordingly, the Company had no inventory on hand as of September 30, 2026.

 

Capitalized Software Development Costs: Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Development costs that are incurred during the application development stage begin to be capitalized when two criteria are met: (i) the preliminary project stage is completed and (ii) it is probable that the software will be completed and used for its intended function. Capitalization ceases once the software is substantially complete and ready for its intended use.

 

Costs incurred during the preliminary project stage of software development and post-implementation operating stages are expensed as incurred. Amortization is calculated on a straight-line basis over three years which is the estimated economic life of the software and is included in the cost of revenue on the condensed consolidated statements of operations.

 

The estimated useful lives of software are reviewed at least annually and the software will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets.

 

Intangible Assets: Intangible assets represent the value the Company paid to acquire assets including a trademark, patent and web domain on June 23, 2021. The allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. These assets are accounted for in accordance with ASC 350-30, Intangibles, General Intangibles Other Than Goodwill. The cost of the assets is amortized over the remaining useful life of the assets as follows:

 

U.S. Method Patent 13.4 years
   
Web Domain Indefinite life
   
Trademark Indefinite life

 

The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances occur which may result in an impact to the value of the assets.

 

10
 

 

Convertible Notes Payable: The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removes certain settlement conditions that were required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation for convertible instruments. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

 

Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) the Company recognizes revenue upon transfer of control of goods, in an amount that reflects the consideration that is expected to be received in exchange for those goods. The Company does not allow for the return of products and therefore does not establish an allowance for returns.

 

To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows:

 

  (i) identify the contract(s) with a customer;
  (ii) identify the performance obligations in the contract(s);
  (iii) determine the transaction price;
  (iv) allocate the transaction price to the performance obligations in the contract(s); and
  (v) recognize revenue when (or as) the Company satisfies a performance obligation.

 

The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer. Beginning April 1, 2025, the Company changed its policy of when title transitions to its customers from upon delivery to upon shipment. Delivery typically occurred within one or two days of shipment, and the Company limited shipping ahead of the end of each reporting period to allow time for delivery. Revenue continues to be recorded when title passes to the customer and, as a result, the change did not have a material impact on the Company’s previously issued consolidated financial statements.

 

The Company includes shipping and handling fees billed to customers in revenue.

 

The Company also generates revenue through SaaS agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term.

 

The Company provides administrative, billing and clinical decision support services utilizing the Company’s internally-developed software. Revenue is recognized each month based on actual services provided during that month.

 

The Company has an agreement with a third party to provide clinical research services utilizing its proprietary internally-developed software. The agreement details the performance obligations of the Company and revenue is recognized as those obligations are met.

 

There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.

 

11
 

 

The Company’s revenues consisted of the following:

 

             
   For the Three Months Ended
September 30,
   For the Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Integrated Service Program  $421,792   $359,376   $1,287,692   $785,506 
Allergy Diagnostic Kit Sales   141,403    216,363    566,231    678,920 
Immunotherapy Treatment Sales   77,581    131,477    262,623    348,691 
Clinical Study Revenue   -    -    29,700    89,100 
Subscription Revenue   8,283    15,876    26,897    34,413 
Shipping and Handling   7,699    11,458    30,253    31,519 
Training & Other Revenue   20,414    2,516    49,951    19,782 
Total revenue  $677,172   $737,066   $2,253,347   $1,987,931 

 

Research and Development: Research and development expense is primarily related to developing and improving methods related to the Company’s technology platform. Research and development expenses are expensed when incurred. For the three months ended September 30, 2026 and 2025, there was $115,074 and $132,769 of research and development expenses incurred, respectively. For the nine months ended September 30, 2026 and 2025, there was $350,604 and $369,166 of research and development expenses incurred, respectively.

 

Stock-based Compensation: The Company applies the fair value method of ASC 718, Share Based Payment, in accounting for its stock-based compensation. The standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values stock-based compensation at the market price for the Company’s common stock and other pertinent factors at the grant date.

 

Earnings Per Common Share: Basic net earnings or (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net earnings or (loss) per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options and warrants to purchase common stock (only if those options and warrants are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported for the three and nine months ended September 30, 2026 as well as the nine months ended September 30, 2025, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the period. For the three months ended September 30, 2025, 8,044,884 common equivalent shares related to Preferred Shares A and A-2 were added to the basic weighted average shares outstanding to arrive at the diluted weighted average shares outstanding.

 

Income Taxes: The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

 

The Company has net operating loss carry forwards of $4,022,572 which begin to expire in 2027. Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization.

 

Recently Issued Accounting Standards

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”), which simplifies the estimation of credit losses on current accounts receivable and contract assets arising from transactions accounted for under ASC 606 through the use of a practical expedient. ASU 2025-05 is effective for annual periods beginning after December 15, 2025, and interim reporting periods within that annual period, with early adoption permitted. The Company adopted this standard in 2026 and determined that it did not have a material impact on the Company’s financial statements.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 beginning with the Form 10-Q for the period ending March 31, 2025 with minimal impact. See Note 12 – Income Taxes.

 

This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

 

12
 

 

Note 4. Accounts Receivable

 

Accounts receivable is recorded in the condensed consolidated balance sheets when customers are invoiced for revenue to be collected and there is an unconditional right to receive payment. Timing of revenue recognition may differ from the timing of invoicing customers resulting in deferred revenue until the Company satisfies its performance obligation.

 

Accounts receivable is presented net of an allowance for credit losses that represents future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The beginning and ending balances of accounts receivable, net of allowance, are as follows:

 

   September 30, 2026   December 31, 2025 
Accounts receivable  $338,923   $220,610 
Allowance for credit losses   (30,000)   (30,000)
Accounts receivable, net  $308,923   $190,610 

 

Note 5. Capitalized Software and Intangible Assets

 

Non-current assets consist of the following at September 30, 2026 and December 31, 2025:

  

   Estimated
Useful
Life
(in years)
   September 30,
2026
   December 31,
2025
 
Capitalized software   3.0   $223,390   $223,390 
Accumulated amortization        (223,390)   (223,390)
Capitalized software, net       $-   $- 
Intangible Assets:               
U.S. Method Patent   13.4   $967,500   $967,500 
Web Domain   N/A    161,250    161,250 
Trademark   N/A    483,750    483,750 
Total Intangible assets       $1,612,500   $1,612,500 
Accumulated amortization        (378,587)   (324,503)
Intangible assets, net       $1,233,913   $1,287,997 

 

Capitalized software represents the development costs for the Company’s internal-use QHSLab platform software. The Company completed testing of its QHSLab platform software application at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. Amortization related to the QHSLab platform was $0 for the three-month periods ended September 30, 2026 and 2025, respectively. Amortization was $0 and $18,616 for the nine-month periods ended September 30, 2026 and 2025, respectively, and is recorded within cost of revenue on the Company’s condensed consolidated statements of operations. There were no impairments recognized during the nine-month periods ended September 30, 2026 and 2025, and the year ended December 31, 2025.

 

The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group, Inc. (“MedScience”) as of June 23, 2021 for total consideration of $1,612,500 which was financed through a combination of restricted stock and a promissory note. The allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. The assets are being amortized over their useful lives beginning July 1, 2021. The Trademark and Web Domain are determined to have an indefinite life and will be tested annually for impairment in accordance with ASC 350-30-35, Intangibles, General Intangibles Other Than Goodwill. There was $18,028 of amortization during each of the three-month periods ended September 30, 2026 and 2025, and $54,084 of amortization expense during each of the nine-month periods ended September 30, 2026 and 2025.

 

The Company evaluates intangible assets with infinite lives for impairment at least annually and evaluates intangible assets with finite lives when events or circumstances indicate an impairment may exist. No impairments or changes in useful lives were recognized during the nine-month periods ended September 30, 2026 and 2025, and the year ended December 31, 2025.

 

13
 

 

Note 6. Loans Payable

 

On November 12, 2025, the Company entered into a fixed-fee short-term loan with its merchant bank and received $114,400 in net loan proceeds. The loan was repaid by the merchant bank withholding an agreed-upon percentage of payments they process on behalf of the Company with a minimum of $14,262 paid every 60 days. Although the loan was originally scheduled to mature in May 2027, it was repaid in full during June 2026. At December 31, 2025, the outstanding loan balance was $90,704, which was split between current and non-current liabilities on the condensed consolidated balance sheets.

 

See additional discussion of loans payable in Note 11 – Related Party Transactions.

 

Note 7. Convertible Notes Payable

 

Convertible notes payable at September 30, 2026 and December 31, 2025 consist of the following:

 

 

   September 30, 2026   December 31, 2025 
Shareholder  $          -   $20,000 
Convertible notes payable gross   -    20,000 
Less: current portion   -    20,000 
Non-current portion  $-   $- 

 

Effective May 7, 2021, the Company issued a Convertible Promissory Note in the original principal amount of $100,000 to a shareholder. The Note bears interest at a rate of ten percent (10%) per annum. The terms and conditions of the Note may not be indicative of those that a third-party investor may agree to. The Note was originally scheduled to mature on September 30, 2022. The maturity date was subsequently extended to December 31, 2023, further extended to December 31, 2024 during the quarter ended March 31, 2024, and further extended to December 31, 2025 during the quarter ended March 31, 2025. Pursuant to the terms of the Note, the outstanding principal and accrued interest were convertible, at the option of the holder, into shares of the Company’s common stock at a conversion price equal to the greater of (i) a twenty-five percent (25%) discount to the fifteen-day average market price of the Company’s common stock or (ii) $0.50 per share.

 

On December 31, 2025, the Company entered into a Promissory Note Modification and Partial Conversion Agreement (“Modification Agreement”) with the holder of the Note. As of that date, the outstanding balance of the Note, including accrued interest, was $146,548. Pursuant to the Modification Agreement, the holder elected to convert $126,548 of outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price of $0.30 per share. As a result of the conversion, the Company issued 421,827 shares of common stock. The converted portion of the Note was extinguished upon issuance of the shares.

 

Following the partial conversion, a remaining balance of $20,000 continued to be outstanding under the Note as of December 31, 2025 and the maturity date was extended to December 31, 2026. The remaining balance continued to bear interest at ten percent (10%) per annum and remained convertible at the option of the holder under the terms of the original Convertible Promissory Note. The Company could prepay the remaining balance, in whole or in part, at any time prior to maturity without penalty.

 

The balance of the Note was paid off in February 2026. The balance of the Note, including accrued interest, was $0 and $20,000 as of September 30, 2026 and December 31, 2025, respectively, and was included in the convertible notes payable line on the accompanying condensed consolidated balance sheets.

 

14
 

 

Note 8. Preferred Stock and Private Placement Offering of Common Stock

 

Issuance of Common Stock and Warrants in a Private Placement Offering

 

On December 26, 2025, the Company accepted subscription agreements from two accredited investors for the purchase of $499,998 of the Company’s common stock and warrants in a private placement offering. Pursuant to the subscription agreements, the Company issued an aggregate of 1,666,663 shares of common stock, par value $0.0001 per share, at a purchase price of $0.30 per share, together with an aggregate of 416,666 warrants to purchase shares of common stock. Each warrant is exercisable at an exercise price of $0.60 per share and expires on December 31, 2030.

 

Series A Preferred Stock

 

The outstanding shares of Series A Preferred Stock have a stated value of $0.25 per share and are initially convertible into shares of common stock at a price of $0.05 per share (subject to adjustment upon the occurrence of certain events). The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote.

 

Series A-2 Preferred Stock

 

The outstanding shares of Series A-2 Preferred Stock have a stated value of $0.16 per share and are convertible into shares of common stock at a price of $0.16 per share (subject to adjustment upon the occurrence of certain events). The rights of holders of the Company’s common stock with respect to the payment of dividends and upon liquidation are junior in right of payment to holders of the Series A-2 Convertible Preferred Shares. The rights of the holders of the Company’s Series A-2 Preferred Shares are pari passu to the rights of the holders of the Company’s Series A Preferred Shares currently outstanding.

 

Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Stock as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.

 

Holders of the Series A-2 Convertible Preferred Stock are entitled to receive cumulative dividends at an annual rate of 7% and payable annually in cash or shares of common stock at the election of the Company in accordance with the Series A-2 Convertible Stock agreement. As of December 31, 2025, the holders of the Series A-2 Preferred Stock had received 94,339 shares of common stock in satisfaction of dividends accrued through December 31, 2025.

 

Note 9. Loss Per Common Share

 

The Company calculates net income or loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net income (loss) per common share were determined by dividing net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period.

 

The Company’s potentially dilutive shares include shares issuable upon exercise or conversion of outstanding common stock options, common stock warrants, convertible debt and preferred shares, if those options, warrants, debt and preferred shares are exercisable or convertible and at prices below the average share price for the period.

 

For the year ended December 31, 2025, 8,044,884 of common equivalent shares related to Preferred Shares A and A-2 were added to the basic weighted average shares outstanding to arrive at the diluted weighted average shares outstanding while other potentially dilutive shares were excluded from the calculation based on the exercise prices for those shares.

 

15
 

 

For the three months ended September 30, 2025, 8,044,884 of common equivalent shares related to Preferred Shares A and A-2 were included in the computation of diluted income per share while others were excluded from the calculation based on the exercise prices for those shares. For the three and nine months ended September 30, 2026 as well as the nine months ended September 30, 2025, the Company’s potentially dilutive shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive since the Company incurred a loss in such period.

 

 

             
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Common equivalent shares   8,044,884    -    8,044,884    8,044,884 
Stock options   -    450,000    -    450,000 
Stock warrants   416,666    -    416,666    - 
Total shares excluded from calculation   8,461,550    450,000    8,461,550    8,494,884 

 

Note 10. Stock-based Compensation

 

During the nine-month periods ended September 30, 2026 and 2025, there was no stock-based compensation associated with stock options. The Company issued 100,000 shares of common stock for services during each of the years ended December 31, 2025 and 2024. A portion of these shares related to services that had not yet been performed at the time of issuance and were recorded as prepaid expenses. Such prepaid amounts were subsequently recognized as expense as the related services were performed. Accordingly, the Company recognized $1,888 of expense in each three-month period ended September 30, 2026 and 2025 associated with shares issued for services in research and development, and $0 and $5,250, respectively, in general and administrative expense. The Company recognized $5,664 of expense in each nine-month period ended September 30, 2026 and 2025 associated with shares issued for services in research and development, and $1,750 and $14,000, respectively, in general and administrative expense.

 

There were no options granted during the nine months ended September 30, 2026 and 2025. There were no options exercised, forfeited or cancelled during either period but all options expired during the year ended December 31, 2025.

 

Options outstanding at September 30, 2025 consist of:

 

Date Issued  Number
Outstanding
   Number
Exercisable
   Exercise Price   Expiration Date
January 1, 2021   450,000    450,000   $0.65   December 31, 2025
Total   450,000    450,000         

 

650,000 outstanding options expired during the nine months ended September 30, 2025.

 

Warrants outstanding at September 30, 2026 consist of:

 

Date Issued  Number
Outstanding
   Number
Exercisable
   Exercise Price   Expiration Date
December 26, 2025   416,666    416,666   $0.60   December 31, 2030
Total   416,666    416,666         

 

550,000 outstanding warrants expired during the nine months ended September 30, 2025.

 

16
 

 

Note 11. Related Party Transactions

 

Due to Related Parties: Amounts due to related parties consist of cash advances received from the Company’s principal shareholder. Some advances bear no interest and are due on demand while a portion has been converted into a loan to the principal shareholder that provides interest at a rate of 10% per annum and matures on March 31, 2027. These terms and conditions may not be indicative of what a third-party investor may agree to. As of September 30, 2026, $97,816 is included in current liabilities on the condensed consolidated balance sheet as a $90,000 loan and accrued interest. As of December 31, 2025, the balance was $91,085 and included in non-current liabilities on the condensed consolidated balance sheet.

 

The Company’s CEO and principal shareholder is a shareholder of MedScience. In addition, the CEO provides services to MedScience for which he is compensated.

 

Note 12. Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Given its history of net operating losses, the Company has determined that it is more likely than not that it will not be able to realize the tax benefit of its net operating loss carryforwards. Accordingly, the Company has not recognized a deferred tax asset for this benefit.

 

The valuation allowance at September 30, 2026 and December 31, 2025 was $818,220 and $794,639, respectively. The net change in valuation allowance for the quarter ended September 30, 2026 was an increase of $10,684, and for the year ended December 31, 2025 was a decrease of $96,285. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. That realization is dependent upon the future generation of taxable income during the period in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred income tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on these considerations, the Company has determined that enough uncertainty exists regarding the realization of the deferred tax asset balance to apply a full valuation allowance against these assets as of September 30, 2026 and December 31, 2025. All tax years remain open for examination by taxing authorities.

 

Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2026 and 2025 are as follows:

 

  

September 30,

2026

  

December 31,

2025

 
Income tax at federal statutory rate   21.00%   21.00%
Valuation allowance   (21.00)%   (21.00)%
Income tax expense   —    — 

 

17
 

 

The Company has net operating loss carry forwards of $4,022,572 which begin to expire in 2027. Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization.

 

For the nine-month period ended September 30, 2026, the Company did not record a tax provision. The Company continues to maintain a valuation allowance against its net deferred tax assets, which will be reassessed as additional information becomes available.

 

Note 13. Segment Information

 

The Company operates as one operating segment. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The CODM used consolidated sales, gross margin and net income (loss) to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the need to allocate its budget to operating expenses and invest in additional resources. The segment assets are equal to the assets presented in the condensed consolidated balance sheets.

 

The significant expenses that are regularly provided to the CODM are disclosed in the condensed consolidated statements of operations as a part of the condensed consolidated net income (loss). See the condensed consolidated financial statements for all financial information regarding the Company’s operating segment.

 

Note 14. Commitments and Contingencies

 

There are no pending or threatened legal proceedings as of September 30, 2026. The Company has no non-cancellable operating leases.

 

Note 15. Subsequent Events

 

Management has evaluated subsequent events through the date of this filing.

 

18
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025 and notes thereto contained elsewhere in this Report, and our annual report on Form 10-K for the twelve months ended December 31, 2025 including the consolidated financial statements and notes thereto contained in such Report. The following discussion and analysis contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements.”

 

Overview

 

We are a healthcare technology company focused on improving preventive and value-based care through digital health solutions and point-of-care services. The Company provides healthcare organizations with technology-enabled programs designed to identify patient health risks, support clinical decision-making, improve patient engagement, and create new opportunities for practice revenue. As part of our mission, we are providing PCPs and other healthcare providers with the software, training and technology necessary to allow them to treat their patients using value-based healthcare, informatics and personalized medicine. Our digital healthcare, clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, to address chronic care and preventive medicine and are reimbursable to the medical practice.

 

Increasingly, regulators and insurance companies recognize what health care technologists have been saying for nearly 20 years, which is that most chronic conditions are better managed with more frequent and short encounters often without a physician’s direct participation, rather than infrequent visits. More health insurers have realized that clinical decision support (“CDS”) technologies such as those provided through our proprietary internally-developed Quality Health System Lab Expert System software (“QHSLab”) can provide the necessary encounters to foster patient compliance in between face to face visits to a physician. As new technologies become available, government health care agencies and health insurers seek to determine the appropriate reimbursement level.

 

Based on the success of PCPs using our QHSLab allergy diagnostics combined with the products acquired from MedScience Research Group, Inc. (“MedScience”), we are increasing our revenues by charging physicians a monthly subscription fee for the use of QHSLab and soliciting additional PCPs to increase their revenues by using our proven revenue generating QHSLab and AllergiEnd® line of products. We also plan to introduce additional point of care solutions, and digital health programs that PCPs can use in their practices. We strive to design our solution so that in all cases, PCPs will be paid under existing government and private insurance programs, based upon analyses conducted utilizing QHSLab and treatments provided as a result of such analyses.

 

Our ability to operate profitably is determined by our ability to generate revenues from the licensing of our QHSLab software and the sale of diagnostic related products and treatment protocols and the provision of services through our QHSLab system. Our ability to generate a profit from these sales is determined by our ability to increase the number of physicians using these products which is highly dependent upon the ability of our physician customers to obtain reimbursement for their services. We will continue to upgrade QHSLab in an effort to increase the number of products sold based upon the services it can provide and for which we are able to charge a fee.

 

Our revenues are, in part, dependent on the ability of our medical practice clients to obtain reimbursement from Medicare, Medicaid, and commercial health insurance providers for clinical services supported by our technology and programs. Government agencies and insurance providers regularly review reimbursement policies, coverage limitation rates, reimbursement rates, documentation requirements and claims adjudication practices to reflect changes in medical practice and the insurance regulations. Changes made by these entities may adversely affect our clients ability to generate revenues and profitability operate their practices, which may reduce demand for our products and services, affect client utilization of our products, result in delayed payments, require adjustments to our service offerings and pricing, and, in extreme circumstances, cause a provider to stop using our products and services entirely. Healthcare reimbursement policies are subject to ongoing review and modification by government and commercial payers, and we cannot predict the timing, nature, or financial impact of future changes. Accordingly, changes in reimbursement policies could materially adversely affect our revenues, operating results, and future growth.

 

Management continuously monitors developments in healthcare reimbursement in an effort to anticipate changes and adapt our programs and services to evolving payer requirements.

 

We operate as a single operating segment and single reportable segment. Our CODM, the Chief Executive Officer, allocates resources and assesses performance based upon condensed consolidated financial information and due to the interconnected relationship of our products which are predominately offered to the same class of customer, manages our business as a single operating segment.

 

19
 

 

Results of Operations during the three and nine months ended September 30, 2026 as compared to the three and nine months ended September 30, 2025

 

Revenues

 

For the three months ended September 30, 2026, we generated revenues of $677,172 compared to $737,066 for the three months ended September 30, 2025, representing a decrease of $59,894, or 8.1%. The decrease was primarily attributable to a 37.0% reduction in combined Allergy Diagnostics and Allergen Immunotherapy treatment revenues, partially offset by a 17.4% increase in revenues generated from our Integrated Service Program (“ISP”).

 

The reduction in allergy-related revenues reflected lower purchasing activity by certain existing physician customers during the quarter. Management is evaluating the extent to which seasonal ordering patterns, physician practice economics, and changes in healthcare insurance affordability and reimbursement policies may have contributed to reduced customer demand. The relative impact of these factors has not yet been established. In September 2026, the Company implemented changes to its vendor relationships expected to reduce the cost of allergy diagnostic kits by approximately 10% to 13%, based on historical product sales mix and revised supplier pricing. These reductions are expected to improve gross margins on future allergy diagnostic kit sales. Despite the decline in allergy-related revenues, the Company continued to experience year-over-year growth in ISP revenues, reflecting the increasing contribution of its technology-enabled healthcare services to its overall revenue mix.

 

For the nine months ended September 30, 2026, we generated revenues of $2,253,347 compared to $1,987,931 of revenues for the nine months ended September 30, 2025. The increase in revenues in the first nine months of 2026 was attributed to a 63.9% increase in revenues generated from ISP services to $1,287,692 compared to $785,506 during the nine months ended September 30, 2025.

 

Our revenues consisted of the following:

 

  

For the Three Months Ended

September 30,

  

For the Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
Integrated Service Program  $421,792   $359,376   $1,287,692   $785,506 
Allergy Diagnostic Kit Sales   141,403    216,363    566,231    678,920 
Immunotherapy Treatment Sales   77,581    131,477    262,623    348,691 
Clinical Study Revenue   -    -    29,700    89,100 
Subscription Revenue   8,283    15,876    26,897    34,413 
Shipping and Handling   7,699    11,458    30,253    31,519 
Training & Other Revenue   20,414    2,516    49,951    19,782 
Total revenue  $677,172   $737,066   $2,253,347   $1,987,931 

 

Cost of Revenues and Gross Profit

 

Cost of revenues consists of the cost of AllergiEnd® test kits and allergen immunotherapy pharmacy prepared treatment sets, shipping costs to our customers as well as administrative and revenue sharing services and labor expenses directly related to ISP sales and the amortization of our capitalized software.

 

For the three months ended September 30, 2026 and 2025, cost of revenues was $208,709 and $243,435, respectively.

 

The Company generated a gross profit of $468,463 during the three months ended September 30, 2026 compared to $493,631 for the three months ended September 30, 2025. Gross margin increased to 69.2% for the quarter compared to 67.0% during the three months ended September 30, 2025.

 

For the nine months ended September 30, 2026 and 2025, cost of revenues was $724,297 and $665,341, respectively.

 

The Company generated gross profit of $1,529,050 during the nine months ended September 30, 2026, compared to $1,322,590 for the nine months ended September 30, 2025. Gross margin increased from 66.5% to 67.9% during the respective periods. The improvement in gross margin was primarily attributable to a favorable shift in revenue mix, including a $502,186 (63.9%) increase in ISP revenue, and operating efficiencies across the Company’s core product lines.

 

Beginning in September 2026, the Company implemented changes to its vendor relationships that are expected to reduce the cost of allergy diagnostic kits by approximately 10% to 13%. Management anticipates that these cost reductions will contribute favorably to gross margins in future periods as the benefits are realized, although the actual impact will depend on sales volumes and product mix.

 

As we continue to introduce new products, the gross margins may vary significantly between periods, due, among other things, to differences among our customers and products sold, customer negotiating strengths, and product mix.

 

Sales and Marketing

 

Sales and marketing expenses consist primarily of costs associated with selling and marketing our products to PCPs, principally ongoing sales efforts to recruit new PCPs and maintain our relationships with PCPs already using our software and products. These expenses include employee compensation and costs of consultants.

 

For the three months ended September 30, 2026, sales and marketing expenses totaled $141,060, an increase of $25,892 compared to $115,168 for the three months ended September 30, 2025.

 

For the nine months ended September 30, 2026, sales and marketing expenses totaled $454,974, an increase of $137,697 compared to $317,277 for the nine months ended September 30, 2025.

 

The increases in sales and marketing expenses for the three and nine-month periods ended September 30, 2026 compared to the same periods in 2025 relate primarily to increases in marketing expenses and payroll-related expenses as we are investing in more sales and marketing activities to support our increasing ISP revenue. We expect our sales and marketing expenses to continue to increase as we seek to build our customer base and launch additional products. Nevertheless, if we are successful in onboarding a sufficient number of PCPs and maintaining our relationships with these PCPs once they begin to fully utilize our products, sales and marketing expenses could decrease as a percentage of revenues, though we may increase our marketing efforts as funds become available.

 

General and Administrative

 

General and administrative expenses consist primarily of personnel and contract labor costs, accounting and legal fees, professional and management consulting services, corporate insurance, and other expenses associated with the administration and operation of the Company.

 

For the three months ended September 30, 2026, general and administrative expenses totaled $244,705, an increase of $113,290, or 86.2%, compared to $131,415 for the three months ended September 30, 2025.

 

For the nine months ended September 30, 2026, general and administrative expenses totaled $768,927, an increase of $282,602, or 58.1%, compared to $486,325 for the nine months ended September 30, 2025.

 

20
 

 

The increase in general and administrative expenses during the periods ended September 30, 2026 was primarily attributable to higher personnel and contract labor costs, additional corporate insurance expenses, and increased administrative and professional service costs. During 2026, the Company introduced Directors and Officers liability insurance as part of its corporate governance and risk management practices, contributing to the increase in insurance expenses compared with the prior-year periods.

 

Management continues to evaluate its administrative cost structure and implement expense management measures while maintaining the personnel, professional services, and corporate infrastructure necessary to support the Company’s operations and regulatory reporting obligations. Future general and administrative expenses will depend on operating requirements, the level of business activity, and management’s ongoing efforts to improve operating efficiency.

 

Research and Development

 

Research and development (“R&D”) expenses primarily consist of costs associated with the development, maintenance, and enhancement of the Company’s proprietary QHSLab technology platform, including software engineering, clinical assessment development, and related digital healthcare programs. R&D costs are expensed as incurred.

 

For the three months ended September 30, 2026, R&D expenses totaled $115,074, a decrease of $17,695, or 13.3%, compared to $132,769 for the three months ended September 30, 2025.

 

For the nine months ended September 30, 2026, R&D expenses totaled $350,604, a decrease of $18,562, or 5.0%, compared to $369,166 for the nine months ended September 30, 2025.

 

Research and development expenses remained relatively consistent with the comparable nine-month period in 2025, reflecting the Company’s continued investment in enhancing its technology platform, expanding its library of clinical assessments, and developing additional digital healthcare programs. Management continues to focus on improving development efficiency while prioritizing technology enhancements and new services that support physician adoption, patient engagement, and revenue growth. Future R&D expenditures will be evaluated in relation to commercial opportunities, operational priorities, and the Company’s objective of achieving sustainable profitability.

 

Other Income and Expense

 

For the three months ended September 30, 2026, interest expense decreased by $60,099 to $2,741 from $62,840 for the three months ended September 30, 2025.

 

21
 

 

For the nine months ended September 30, 2026, interest expense decreased by $175,412 to $19,482 from $194,894 for the nine months ended September 30, 2025.

 

The decrease is driven by the conversion and settlement of multiple loans during the fourth quarter of 2025 including the elimination of default interest associated with certain of the notes.

 

Net Operating Income (Loss); Net Income (Loss)

 

Although revenue increased approximately 13.4% during the nine months ended September 30, 2026, the Company reported an operating loss of $99,539, compared to operating income of $95,738 during the comparable prior-year period. The change in operating results was primarily attributable to increased sales and marketing expenditures and general and administrative expenses associated with expanding the Company’s physician network, commercial operations, and administrative capabilities. These expenditures were partially offset by increased revenue and gross profit, as well as modest reductions in research and development expenses.

 

For the nine months ended September 30, 2026, the Company reported a net loss of $119,021, compared to a net loss of $99,156 during the comparable prior-year period. The increase in operating expenses was substantially offset by a reduction in interest expense, which decreased from $194,894 in 2025 to $19,482 in 2026, reflecting the Company’s reduced debt obligations.

 

Management remains focused on improving operating efficiency, expanding recurring revenues, and achieving sustainable profitability. The continued growth of the Company’s Integrated Service Program and investment in its technology platform are expected to support greater operating leverage as revenues increase. Management intends to maintain a disciplined approach to expenditures, prioritizing investments in technology, customer acquisition, and commercialization activities that support revenue growth and improved financial performance. Future operating results will depend on the Company’s ability to increase revenues while effectively managing operating costs.

 

Liquidity and Capital Resources

 

Liquidity is a measure of a company’s ability to generate sufficient funds to support its operations, meet financial obligations, and fund future growth.

 

As of September 30, 2026, the Company had current assets of $519,108, consisting primarily of cash and cash equivalents of $190,464, accounts receivable, net, of $308,923, and prepaid expenses and other current assets of $19,721. Current liabilities totaled $247,114, including accounts payable of $135,616, other current liabilities of $13,682, and amounts due to a related party of $97,816. The Company had no outstanding long-term liabilities as of September 30, 2026.

 

At December 31, 2025, the Company had current assets of $883,009, including cash and cash equivalents of $636,157, accounts receivable, net, of $190,610, inventory of $35,790, and prepaid expenses and other current assets of $20,452. Current liabilities totaled $449,860, including accounts payable of $326,431, other current liabilities of $17,858, and current portions of loans and convertible notes totaling $105,571. Long-term liabilities consisted of outstanding loan balances of $96,218.

 

Cash and cash equivalents decreased by $445,693 during the nine months ended September 30, 2026, from $636,157 at December 31, 2025 to $190,464 at September 30, 2026. The decrease primarily reflected $334,989 of cash used in operating activities to support sales growth and $110,704 used in financing activities, principally for the repayment of outstanding debt obligations.

 

Cash used in operating activities reflected the Company’s operating losses, increased working capital requirements, and continued investment in sales and marketing, technology development, and administrative capabilities to support its expanding physician network and healthcare service programs. Accounts receivable increased by $118,313 during the period, reflecting additional working capital requirements associated with the Company’s revenue growth. These cash requirements were partially offset by reductions in operating liabilities and other changes in working capital.

 

During the nine-month period, the Company substantially reduced its outstanding debt obligations, including repayment of its remaining loan balances, contributing to a significant reduction in interest expense compared with the prior-year period. Management believes the reduction in debt has strengthened the Company’s financial flexibility and reduced future debt servicing requirements.

 

Management continues to focus on improving operating cash flow through disciplined expense management, timely collection of accounts receivable, growth in recurring revenues, and improvements in gross margins. The Company is also prioritizing investments in technology, customer acquisition, and commercialization activities that support revenue growth and operating efficiency. Management believes these initiatives may contribute to improved operating leverage as the business expands, although the timing and extent of such improvements remain uncertain.

 

Notwithstanding these initiatives, the Company incurred a net loss of $119,021 and used $334,989 in cash from operating activities during the nine months ended September 30, 2026. The Company’s ability to meet future operating requirements will depend on its ability to generate sufficient revenues, improve operating cash flows, and collect outstanding receivables. Management’s plans are focused on achieving sustainable profitability and positive operating cash flows; however, the Company has not yet demonstrated sustained profitability from operations, and substantial doubt remains regarding its ability to continue as a going concern.

 

Additional financing may be required if operating results or cash collections do not meet management’s expectations. Although the reduction in outstanding debt may provide greater financial flexibility, there can be no assurance that additional financing will be available on commercially reasonable terms, if at all. Management will continue to evaluate opportunities to strengthen liquidity and capital resources while maintaining a disciplined approach to operating expenditures and long-term growth initiatives.

 

22
 

 

Plan of Operation and Funding

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2026, the Company had an accumulated deficit of $4,022,572 and reported a net loss of $119,021 for the nine months then ended. For the year ended December 31, 2025, the Company reported net income of $457,417, principally attributable to a gain of $1,145,695 from the extinguishment of debt. The Company used $334,989 in cash from operating activities during the nine months ended September 30, 2026, compared with cash generated from operating activities of $178,118 for the year ended December 31, 2025.

 

Despite improvements in revenue, gross margins, and the substantial reduction of outstanding debt obligations, the Company’s history of operating losses and negative operating cash flows raises substantial doubt about its ability to continue as a going concern. The Company’s ability to continue operations is dependent upon achieving sustainable positive operating cash flows or obtaining additional financing, if necessary. The condensed consolidated financial statements do not include any adjustments to the recoverability or classification of assets or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

 

For the nine months ended September 30, 2026, revenue increased approximately 13.4% compared with the corresponding prior-year period, supported by continued growth in the Company’s ISP. However, increased operating expenses associated with sales and marketing, personnel, and administrative infrastructure exceeded the growth in gross profit, resulting in an operating loss for the period. Management is focused on improving operating efficiency, controlling expenditures, and expanding recurring revenue streams to support sustainable profitability.

 

As of September 30, 2026, the Company maintained cash and cash equivalents of $190,464, net accounts receivable of $308,923, and positive working capital of $271,994. Management expects working capital requirements to fluctuate with changes in revenue, customer billing and collection cycles, and the timing of operating expenditures. The continued expansion of service-based revenues may result in increased accounts receivable balances, requiring effective collection practices and disciplined working capital management.

 

The Company has substantially reduced its outstanding debt obligations, resulting in lower interest expense and reduced debt servicing requirements. Management intends to prioritize funding operations through internally generated cash flows and the collection of outstanding receivables while maintaining a disciplined approach to expenditures. The Company’s operating strategy emphasizes growth in higher-margin recurring revenues, improvements in gross margins, and selective investment in technology development, customer acquisition, and commercialization activities that support operational efficiency and long-term growth.

 

Management continues to evaluate opportunities to improve liquidity and strengthen the Company’s financial position. Although management believes that revenue growth, improved cost management, and anticipated collections of outstanding receivables may support future operating requirements, the Company has not yet demonstrated sustained positive operating cash flows. Accordingly, there can be no assurance that existing resources and future operating cash flows will be sufficient to fund operations over the next twelve months.

 

If additional capital becomes necessary, the Company may seek financing through debt, equity, or other arrangements. In particular, delays in collecting outstanding accounts receivable or increased working capital requirements may necessitate additional short-term borrowing to support ongoing operations. Management will continue to evaluate available financing alternatives based on the Company’s liquidity requirements, anticipated operating cash flows, financing costs, and the interests of its shareholders. There can be no assurance that additional financing will be available on acceptable terms, if at all.

 

Additional issuances of equity or convertible securities could result in dilution to existing shareholders and may involve terms or preferences senior to those of the Company’s common stock. Additional borrowings could increase debt servicing obligations, require collateral or restrictive covenants, and limit financial flexibility. There can be no assurance that additional financing will be available on commercially reasonable terms, if at all. If sufficient capital is unavailable when required, the Company may need to reduce operating expenditures, delay planned investments, or limit business expansion, which could adversely affect its operations and financial performance.

 

The Company’s ability to obtain additional capital, if required, will depend on prevailing financial market conditions, investor demand, and its operating performance. General economic conditions, inflation, healthcare reimbursement policies, geopolitical developments, and other risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 may affect both the Company’s operating results and its access to financing.

 

Management remains focused on strengthening the Company’s financial position through disciplined capital allocation, improved operating cash flows, and the continued development of its technology-enabled healthcare services. The Company’s objective is to achieve sustainable profitability while maintaining the financial flexibility necessary to support future growth opportunities.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of disclosure controls and procedures.

 

As of September 30, 2026, our chief executive officer, who is also our chief financial officer conducted an evaluation regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act). Based upon the evaluation of these controls and procedures as provided under the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013), our chief executive officer/ chief financial officer concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report. Many of these deficiencies stem from a lack of adequate personnel, including individuals with experience in financial reporting. Management has identified corrective actions for the weakness and will periodically reevaluate our ability to add personnel and implement improved review procedures as they can be supported by the growth in our business.

 

Changes in internal controls.

 

During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

23
 

 

PART II - OTHER INFORMATION

 

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1. Description of Business, subheading Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition or future results.

 

ITEM 6. EXHIBITS.

 

(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

 

Exhibit No.   Description
     
3.1   Articles of Incorporation (incorporated herein by reference to Exhibit B to the Information Statement on Form 14-C filed June 21, 2021)
     
3.2   By-Laws (incorporated herein by reference to Exhibit C to the Information Statement on Form 14-C filed June 21, 2021).
     
4.1   Certificate of Designation authorizing issuance of Series A Preferred Stock (incorporated herein by reference to Exhibit D to the Information Statement on Form 14-C filed June 21, 2021)
     
4.2   Certificate of Designation authorizing the issuance of the Series A-2 Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Report on Form 8-K filed December 30, 2021)
     
31   Certification of CEO and CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32   Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

24
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

 

QHSLab, Inc.  
     
By: /s/ Troy Grogan  
  Troy Grogan  
  Chief Executive Officer and Chief Financial Officer  
     
Date: November 12, 2026  

 

25

 

Keep reading